Gemini
Senior Member
- Messages
- 1,176
- Location
- East Coast USA
A new class of cancer drugs, antibodies that block T-cell receptors (PD-1, CTLA-4) and unleash T-cells against tumors, are causing rapid onset type 1 diabetes and other autoimmune diseases in some patients.
Heralded as the 2013 "Breakthrough of the Year" these drugs have delivered impressive results.
Researchers are rushing to determine which patients receiving checkpoint inhibitors are at high risk and to learn how this unusual side effect causes autoimmune disease.
"These [patients] are human experiments of the autoimmune process."
Source: 17 Nov 2017, Science Magazine
http://science.sciencemag.org/content/358/6365/852.full
Need to follow this developing story i.e. Ron Davis notes discoveries in one field often benefit another.
@Janet Dafoe (Rose49)
Heralded as the 2013 "Breakthrough of the Year" these drugs have delivered impressive results.
Researchers are rushing to determine which patients receiving checkpoint inhibitors are at high risk and to learn how this unusual side effect causes autoimmune disease.
"These [patients] are human experiments of the autoimmune process."
Source: 17 Nov 2017, Science Magazine
http://science.sciencemag.org/content/358/6365/852.full
Need to follow this developing story i.e. Ron Davis notes discoveries in one field often benefit another.
@Janet Dafoe (Rose49)